Market Newsdesk

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced that another Texas school district has selected C-Bond BRS (ballistic-resistant system) to help protect its students and faculty from gun violence or other means of forced entry. C-Bond BRS has already been installed in three of the more than 30 elementary schools in the district in Central Texas, and installation at one of the district’s four high schools is underway.

C-Bond BRS is a ballistic-resistant film system that consists of the patented C-Bond glass strengthening technology and security film. The C-Bond technology chemically bonds to the defects randomly distributed on the glass surface to increase impact resistance and prevent breakage. The combination of the C-Bond technology combined with multiple layers of security film have been validated by an independent third-party laboratory to provide National Institute of Justice (NIJ) Level I, Level IIA, Level II, and Underwriters Laboratories (UL) 752 ballistic-resistant protection.

“It is apparent that building security – whether at schools, stores, offices, or other facilities – is more important than ever,” stated Scott R. Silverman, Chairman and CEO of C-Bond. “The current unrest in our country, previous school shootings, and other tragedies are forcing our school systems and society as a whole to put stronger security measures in place. C-Bond BRS provides a cost-effective and robust solution to help protect innocent lives.”

C-Bond BRS has been installed in numerous schools, government buildings, and other high-security facilities around the country. C-Bond’s glass strengthening technology is protected by 22 patents and patent pending applications.

About C-Bond

C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based advanced nanotechnology company and marketer of the patented C-Bond technology, developed in conjunction with Rice University and independently proven to significantly strengthen glass in key automotive and structural applications. The Company’s Transportation Solutions Group sells C-Bond nanoShield, a liquid solution applied directly to automotive windshields, sold through distributors. The Company’s Safety Solutions Group sells ballistic-resistant glass solutions directly to private enterprises, schools, hospitals and government agencies. The Company also sells disinfection products, including MB-10 Tablets. For more information, please visit our website: www.cbondsystems.com, Facebook: https://www.facebook.com/cbondsys/ and Twitter: https://twitter.com/CBond_Systems.

Forward-Looking Statements 

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, C-Bond’s ability to raise capital; the Company’s ability to successfully commercialize its products; the effect of the COVID-19 global pandemic on the Company’s and its customers’ ability to operate; the Company’s ability to source materials; as well as other risks. Additional information about these and other factors may be described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including its Form 10-K filed on March 25, 2020, its Forms 10-Q filed on November 16, 2020, August 14, 2020, and May 15, 2020, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Allison Tomek
C-Bond Systems
6035 South Loop East 
Houston, TX 77033
[email protected]

Brokers and Analysts:
Chesapeake Group
410-825-3930
[email protected]

TAMPA, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sports Venues of Florida, Inc., (OTCMKTS: BTHR) (“Sports Venues of Florida”, “BTHR”, or the “Company”), an emerging leader in the youth sports, family sports entertainment, and eSports markets, CEO John V. Whitman Jr., talks openly about the State of the Company.

In my opinion being a responsible CEO of a public company is not simply about disclosing required financial information on a timely basis but informing shareholders, interested parties and prospective shareholders what progress the Company is making or has made in terms of fulfilling its business plan. The Company files quarterly and annual financial information disclosures with OTCMarkets.com. To view these filings please follow the following link: https://www.otcmarkets.com/stock/BTHR/disclosure. For information about the Company that is not required in financial disclosures please continue reading.

We are an early revenue development stage Company. To standout above the others, we believe it is important to provide the public additional tools for which to assemble a clearer picture of the status of their Company and its prospects for success in the future. We are sharing analytics from our various websites, social media accounts that will provide critical data and trends of engagements by the public. These engagements or clicks tell management if the Company is successfully getting its message to its customers. The paragraphs below will provide the public with real data about their Company.

Since February 25, 2020, the Company has issued forty-four press releases prior to this one. These press releases have reached 40 countries to more than 6,800 media outlets. We have attained a total audience reach of 137,700,965. Total impressions have exceeded 1.89 million and more than 350,000 traditional and social media views. (These analytics were supplied by NewMediaWire on the evening of January 12, 2021).  To find our most recent press release or to read past press releases you can visit Yahoo Finance, Bloomberg, E*Trade, Ameritrade, OTCMarkets, MSN, CNBC, Business Insider, NASDAQ and all the other thousands of businesses that offer stock quotation or news services.

Twitter has been an amazing resource for us. Since February 25, 2020, the number of viewers is virtually impossible to determine, certainly in the millions, but we can provide the number of people who read our tweets and were motivated to a Call to Action. Hits generated from hashtags have been 20,377. Click throughs from affiliated networks 13,926. We received 6,319 email hits. People have clicked through to our LinkedIn page 12,501 times and our Facebook page 11,440 times. We own three Twitter handles and between the three we have over 18,500 followers.

GGToor.com/ website was launched in April 2020. That month we only had 8 visitors. We are pleased to announce we had 6,725 in November 2020 and 8,625 in December 2020. Since inception the site has enjoyed 29,710 impressions with 21,682 visitors who stayed an average of 4-minutes each. The number of followers and subscribers has grown to 1,552. Prior to November 2020 GGToor.com had no followers or subscribers. GGToor.com is averaging 338 registered players per online tournament; this is up from 19 registered players for our first tournament. Total hits to our website have been 246,522 with 161,612 from the United States, 11,071 from Great Britain, 9,322 coming from Canada, 5,626 coming from Germany. These four countries have made up 76% of our total hits with the remaining 24% coming from 75 other countries. What this tells us is we are truly building a Global Audience and a Global Following that based on current trends is growing by approximately 35% per month.

Twitch is the media which we use to broadcast our tournament events. Since we began running tournaments in May 2020, we have enjoyed a total of 14,215 viewers. We have 956 followers or subscribers. We do not have an average length of time each viewer stays watching or engaging with our broadcast but each averages 10-hours. Our Twitch channel has grown by 36% since August and we anticipate this growth model to continue in 2021.

Our Discord channel which only started in late September 2020 has enjoyed 10,686 message exchanges, 2,737 visitors, 1,365 subscribers or followers and has experienced growth averaging 25% per month.

Our common stock which trades under the symbol BTHR:US has traded 68,701,298 shares or an average daily volume of 534,855 (numbers pulled from Yahoo Finance at 2:22 pm Est on Tuesday, January 12, 2021). The Company has 121 shareholders of record. The Company has 937,500,000 common shares authorized with 78,210,271 issued and outstanding. The common shares held at DTC that are available to trade are only 16,394,537 (numbers pulled from OTCMarkets.com at 2:27 pm Est on January 12, 2021).

The quarter ended November 20, 2020 was the first time in the Company’s history it was able to report revenue. Although modest, sales of $4,579 for the period ended November 30, 2020, marks the beginning of concept to reality in just 7-short months. Management is delivering exactly what it promised the public it would deliver. Sports Venues of Florida, Inc., is certainly making a splash across the entire globe and with the revenue tap turned on, we believe the growth in 2021 will be unprecedented. We are convinced GGToor.com will become a Global Leader in the eSports space.

We strive to be a very transparent Company. If shareholders, prospective shareholders or interested parties have questions, comments or concerns we want to hear from you. Please visit any of the links below to contact us. I want to thank everyone who has supported us throughout our journey and express my appreciation to all who will support our Company in the future. We are working for you!

John V. Whitman Jr., CEO/Chairman/President

About BTHR

Sports Venues of Florida, Inc., is a developmental stage company engaged in the business of eSports, and the development of youth sports and family entertainment complexes. The company, through its wholly owned subsidiary, Shadow Gaming, Inc., has aggressively entered the eSports market. Shadow Gaming’s new portal GGToor.com has been launched and is one of the most comprehensive gaming portals in the world. The Company is now accepting subscriptions from players, gamers, and tournament organizers. To register logon to https://ggtoor.com/. In addition, the company plans on operating a few subsidiary companies from high tech data management businesses to product and support businesses. Finally, the Company is actively looking for locations to build indoor eSports arenas that will host major international gaming tournaments.

Forward-Looking Statements. This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “expect,” “expectation,” “believe,” “anticipate,” “may,” “could,” “intend,” “belief,” “plan,” “estimate,” “target,” “predict,” “likely,” “seek,” “project,” “model,” “ongoing,” “will,” “should,” “forecast,” “outlook” or similar terminology. These statements are based on and reflect our current expectations, estimates, assumptions and/ or projections as well as our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements are neither predictions nor guarantees of future events, circumstances or performance and are inherently subject to known and unknown risks, uncertainties and assumptions that could cause our actual results to differ materially from those indicated by those statements. There can be no assurance that our expectations, estimates, assumptions and/or projections, including with respect to the future earnings and performance or capital structure of Sports Venues of Florida, Inc.

For Additional Information Contact:
John V Whitman Jr.,
[email protected]
https://sportsvenues.net/

https://ggtoor.com/

Rapid Transition from a Studio-Based Model to a Home-Based Model During COVID 19 Shutdown Results in Limited Impact to Revenue

Boca Raton, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Grom Social Enterprises, Inc. (OTCQB: GRMM) (Grom the “Company”, “we”, “us”, or “our”), the developer of Grom Social, a leading social media platform for kids and original children’s entertainment content provider, today announced that its wholly-owned subsidiary, Top Draw Animation, and its ability to transition from a studio-based model to a home-based model in a 48 hour period, allowed the company to continue production on then ongoing projects resulting in a minimum impact on revenue during the initial COVID months. Total revenue for 2021 from Grom’s animation subsidiary stands at $6.5 million, and places it close to the $7.0 million pre-COVID booked business going into 2020 and well ahead of the same period in 2019. Unused capacity remains for the second half of the year, which the Company expects to fulfill with the renewal of existing projects/series, as well as new projects that have already undergone successful testing valued in excess of $2.5 million. Due to confidentiality, the partners and project names cannot be disclosed.

“This significantly allows Grom to get back to pre-COVID production levels and overall revenue projections for 2021, following delays of up to 9 months by major studio clients,” said Darren Marks, Chairman and Chief Executive Officer of Grom Social Enterprises, “and is testament to the quality and reliability of all our platforms and to the success of our universal strategies in the kids space.”

Marks continued, “The overall strength of our subsidiaries continues to provide a meaningful revenue base with attractive gross margins as we begin to market our exciting COPPA-compliant kids app, Grom Social, that offers solutions to many of today’s on-line issues plaguing Facebook, Snapchat and TikTok, among others. Given these challenges, we believe there is a significant opportunity to accelerate our user growth and efficiently monetize the platform in the near-term, while ultimately, driving long-term, sustainable value for our shareholders.”

About Top Draw Animation, Inc.

TDA is an award-winning producer of top-quality 2D animation for television markets around the world and for leading companies such as Disney Television Animation, DreamWorks Television and Nickelodeon.  The company employs over 500 artists in its 30,000 square foot, state-of-the-art studio in Manila, the Philippines and has accumulated an impressive portfolio of TV animation totaling more than 2,000 half hours.  For more information please visit our website at www.topdrawanimation.com

About Grom Social Enterprises, Inc.

Grom Social Enterprises, Inc. (OTCQB: GRMM) is a leading social media platform and original content provider of entertainment for children under 13 years of age; providing safe and secure digital environments for kids that can be monitored by their parents or guardians. The Company has several operating subsidiaries, including Grom Social, which delivers its content through mobile and desktop environments (web portal and apps) that entertain children, let them interact with friends, access relevant news, and play proprietary games, while teaching them about being a good digital citizen. The Company owns and operates Top Draw Animation, Inc., which produces award-winning animation content for some of the largest international media companies in the world. Grom Social Enterprises also includes Grom Educational Services, which has provided web filtering services for K-12 schools, government and private business. For more information, please visit gromsocial.com. 

Safe Harbor Statement

This press release may contain forward-looking statements about Grom Social Enterprises activities that are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods, and other risks set forth in the Company’s filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including, but not limited to general stock market conditions. We have incurred and will continue to incur significant expenses in the expansion of our existing and new service lines, noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long-term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations where we will be providing services, the impact of which cannot be predicted at this time. All forward-looking statements speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements or other information contained herein. Stockholders and potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Investor Relations Contact:

TraDigital IR

Kevin McGrath
+1-646-418-7002
[email protected]

BOCA RATON, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that the Tri-County Suburban REALTORS® (“TCSR”) has contracted to make FOREWARN® services available for the 8,500+ REALTOR® members it serves in Chester, Delaware and Montgomery counties to promote proactive real estate agent safety.

Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided by potential clients — using just a phone number. FOREWARN allows agents to properly and safely plan for showings with a higher level of confidence.

The FOREWARN services purchased by TCSR will be available to the 8,500+ real estate agent membership at no additional cost to individual agents.

“It is my great pleasure to announce this partnership with FOREWARN to provide an added layer of proactive safety and intelligence for all our members,” said Anne Marie Matteo, President and CEO of Tri-County Suburban REALTORS®. “Agent safety is a leading concern. By partnering with FOREWARN, we can empower our members with unobtrusive identity and risk verification so they can enter showings and meetings with increased certainty and confidence.”

On January 4, 2021, existing TCSR members received specific instructions on how to move forward with activating their FOREWARN subscription.

All other real estate agencies and agents can learn more about FOREWARN at www.forewarn.com.

About FOREWARN®

At FOREWARN, we bring instant knowledge through innovative solutions to ensure safer engagements and smarter interactions. Leveraging powerful analytics and a massive data repository, our solutions enable organizations to gain real-time knowledge, for purposes such as verifying identity, searching for criminal histories, and validating information. Risk assessment and due diligence at your fingertips™.

RELATED LINKS:
www.forewarn.com

About red violet®

At red violet, we believe that time is your most valuable asset. Through powerful analytics, we transform data into intelligence, in a fast and efficient manner, so that our clients can spend their time on what matters most – running their organizations with confidence. Through leading-edge, proprietary technology and a massive data repository, our analytics and information solutions harness the power of data fusion, uncovering the relevance of disparate data points and converting them into comprehensive and insightful views of people, businesses, assets and their interrelationships. We empower clients across markets and industries to better execute all aspects of their business, from managing risk, recovering debt, identifying fraud and abuse, and ensuring legislative compliance, to identifying and acquiring customers. At red violet, we are dedicated to making the world a safer place and reducing the cost of doing business. For more information, please visit www.redviolet.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether FOREWARN will address real estate agent safety and whether FOREWARN will empower TCSR’s members with unobtrusive identity and risk verification so they can enter showings and meetings with increased certainty and confidence. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release and are advised to consider the factors listed above together with the additional factors under the heading “Forward-Looking Statements” and “Risk Factors” in red violet’s SEC Filings. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Camilo Ramirez
Red Violet, Inc.
561-757-4500
[email protected]

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Franklin Wireless Corp. (OTCQB: FKWL), a market leader in broadband data communications, today announced the successful customer trial of Pintrac Drive, an aftermarket On-Board Diagnostic (OBDII) device that enables non-connected cars to connect to global 4G LTE networks for enhanced services and broadband wireless connectivity.

With easy plug and play the ODB device is compatible with virtually any car manufactured after 1998 and connects easily to US and International 4G LTE networks without the need of an installation technician. Once installed, the device provides on-demand live vehicle tracking, high-speed alerts, vehicle health diagnostic data, collision detection, air quality monitoring for Carbon Monoxide and other contaminates, and a host of other features and functions.

“Pintrac Drive is a turn-key solution for carriers. The device with its customizable cloud-based data services, and mobile applications are all part of the package,” stated, David Lee, Franklin’s COO.

Specific features include:

• Live Vehicle Tracking using GPS and GLONASS satellite tracking technology to pinpoint the vehicles location.
• Vehicle Health & Diagnostic
  Data can provide timely maintenance information before a costly repair is needed. The device provides an easy-to-understand description of the problem along with the DTC (Diagnostic Trouble Code).
• Broadband Wi-Fi allows vehicle occupants to connect to the web at broadband speed allowing up to 10 simultaneous users to stream a movie or catch up on emails while on the road.
• Create Custom Geofence Zones to accurately know when and where the vehicle enters or exits up to five pre-defined Geofence zones.
• Collison Detection to notify loved ones in case the driver or other occupants are involved in a crash and may be unable to call for help.
• Air Quality monitoring able to detect exhaust leaks and prevent poisoning to vehicle occupants.

The Pintrac Drive app is designed to work with both Apple and Android devices.

About Franklin

Franklin Wireless Corp. (FKWL) is a leader in innovative hardware and software products that support smart tracking and the Internet of Things (IoT), as well as intelligent wireless broadband solutions including mobile hotspots, routers and modems. For more information, please visit www.franklinwireless.com.

Safe Harbor Statement:

Certain statements in this press release constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements, expressed or implied by such forward-looking statements.

Franklin Wireless Corp.

+1 858 623 0000
[email protected]

HERZLIYA, Israel, Jan. 13, 2021 (GLOBE NEWSWIRE) —

Safe-T®
Group Ltd.
(NASDAQ, TASE: SFET), a provider of secure access solutions for on-premise and hybrid cloud environments, continues to strengthen collaboration with its distribution partners and will participate in two virtual events during January 2021.

The virtual events will be held with four of the Company’s partners, including HTC Global Services and Softprom Distribution GmbH.  HTC Global Services is a global provider of information technology services and solutions in India.  Softprom Distribution GmbH is a leading Value-Added IT distributor in the Commonwealth of Independent States (“CIS countries”), European countries, and more.

Eitan Bremler, Co-Founder & VP Corporate Development at Safe-T Group, will present its advanced solutions for the next generation VPN.  Safe-T Group’s ZoneZero™ VPN revolutionizes secure access by introducing Zero Trust Network Access (ZTNA) to existing VPN infrastructures.  As part of the ZoneZero™ Perimeter Access Orchestration suite, ZoneZero™ VPN provides application-layer policy monitoring and enforcement, integration of MFA to any application or service, and true separation of the data plane and control plane – all on top of the existing infrastructure.

The HTC virtual event will take place on January 20, 2021 and can be accessed here: https://www.brighttalk.com/webcast/17734/458806  

The Softprom virtual event will take place on January 27, 2021 and can be accessed here:  https://www.brighttalk.com/webcast/17734/461281?utm_source=Safe-T&utm_medium=brighttalk&utm_campaign=461281

About Safe-T®

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of Zero Trust Access solutions which mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity.

Safe-T’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Zero Trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

Safe-T’s wide range of access solutions reduce organizations’ attack surface and improve their ability to defend against modern cyberthreats. As an additional layer of security, our integrated business-grade global proxy solution cloud service enables smooth and efficient traffic flow, interruption-free service, unlimited concurrent connections, instant scaling, and simple integration with our services.

With Safe-T’s patented reverse-access technology and proprietary routing technology, organizations of all size and type can secure their data, services, and networks against internal and external threats.

At Safe-T, we empower enterprises to safely migrate to the cloud and enable digital transformation.

Safe-T’s solutions on AWS Marketplace is available here

For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses strengthening collaboration with its distribution partners. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

INVESTOR RELATIONS CONTACTS:

Gary Guyton
MZ Group – MZ North America
469-778-7844
[email protected]
www.mzgroup.us

Michal Efraty
+972-(0)52-3044404
[email protected]

TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) (the “Company”), who through its wholly-owned subsidiary, PharmaTher Inc., is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture Market (“OTCQB”) effective today.

The Company’s U.S. listing will trade under the symbol “PHRRF” while the Company’s primary Canadian listing will continue to trade on the Canadian Securities Exchange under “PHRM”.

Fabio Chianelli, CEO of the Company commented, “We are focused on developing our clinical-stage product pipeline of novel uses and delivery of ketamine for U.S. FDA approval to treat mental health, neurological and pain disorders, and with our common shares listed on the OTCQB it will help us to broaden our awareness and shareholder base with institutional and retail investors in the U.S.”

The Company has also applied to the Depository Trust Company (“DTC”) for DTC eligibility, which would greatly simplify the process of trading the Company’s common shares. The Company expects to receive DTC eligibility approval shortly.

Investors can find real-time quotes and market information on the Company at https://www.otcmarkets.com/stock/PHRRF/overview.

About PharmaTher Inc.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat mental health, neurological and pain disorders.

Learn more at:  PharmaTher.com and follow us on Twitter, LinkedIn and Facebook.

For more information, please contact:        

Fabio Chianelli
Chief Executive Officer
PharmaTher Inc.
Tel: 1-888-846-3171
Email: [email protected]
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.        

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the approval of OTCQB Venture Market listing, application of DTC eligibility, broadening awareness and shareholder base of U.S. institutional and retail investors, and meeting milestones of FDA-approved ketamine for mental health, neurological and pain disorders, FDA approval, intellectual property portfolio,
psychedelic pharmaceuticals,
psilocybin and ketamine programs and product developments. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on the Company’s profile at 



www.sedar.com



.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

— Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets —

—
Sarepta to have options for an exclusive license to Genevant’s
LNP
technology
for
four
neuromuscular
indications
—

— Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future milestones and royalties —

CAMBRIDGE, Mass., VANCOUVER, British Columbia, and BASEL, Switzerland, Jan. 13, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced a research collaboration and option agreement for the delivery of LNP-gene editing therapeutics in Sarepta’s pipeline for neuromuscular diseases. LNPs offer the potential for a non-viral approach to gene editing and can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of gene editing cargo, such as CRISPR-Cas, to target tissues.

Gene editing has the potential to revolutionize the treatment of diseases caused by genetic mutations – including rare neuromuscular diseases – by permanently altering genes that lead to disease. Sarepta is pursuing a variety of approaches to genetic medicine including exon skipping, gene therapies and gene editing in pursuit of cures for rare diseases.

Under the terms of the agreement, Genevant will design and collaborate with Sarepta in the development of muscle targeted LNPs to be applied to gene editing targets in early stage development.  Sarepta will have rights to an exclusive license to Genevant’s LNP technology for up to four neuromuscular indications, including Duchenne muscular dystrophy. Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future development, regulatory and commercial milestones and tiered royalties ranging from the mid-single to low-double digits on future product sales.

“As Sarepta works to advance precision genetic medicine across multiple modalities, we’ve invested in partnering and research efforts focused on improving the utility and benefit of gene-based medicines and providing the greatest possible outcome to patients. This includes advancing our pre-clinical gene editing program, looking at both viral and non-viral methods to produce a functional gene in order to treat a broad range of neuromuscular diseases,” said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. “Genevant’s established leadership and proven LNP technology offers the potential to deliver gene editing machinery to targeted tissue through a non-viral delivery approach. Applying this science to neuromuscular diseases fits squarely within our mission to translate scientific breakthroughs into meaningful advances for patients whose lives have been impacted by rare disease.”

“Genevant scientists have been at the forefront of LNP delivery of nucleic acids for over 20 years. Our platform is the most clinically validated in the space and is the delivery technology behind the first nucleic acid-LNP product to have achieved FDA approval,” said Pete Lutwyche, Ph.D., president and chief executive officer, Genevant Sciences Corporation. “Efficient, optimized delivery is often the difference between successful and unsuccessful nucleic acid drug development, and we are excited to bring our experience to Sarepta’s gene editing programs in neuromuscular disease where new options – and new approaches – are desperately needed.”

About Genevant Sciences

Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development.  The Company’s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Company’s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing.  Genevant Sciences is committed to transforming the future of human health. For more information, please visit www.genevant.com.

About Sarepta Therapeutics

At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

This press release contains “forward-looking statements.” Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the parties’ obligations and responsibilities under the agreement, potential payments and fees and Sarepta’s right to an exclusive license to Genevant’s LNP technology for up to four neuromuscular indications; the potential benefits of LNPs, including offering a non-viral approach to gene editing that can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of gene editing cargo, such as CRISPR-Cas, to target tissues; the potential for gene editing to revolutionize the treatment of diseases caused by genetic mutations – including rare neuromuscular diseases – by permanently altering genes that lead to disease; the goal of Genevant to design and collaborate with Sarepta in the development of muscle-targeted LNPs that can be applied to gene editing targets in early stage development;  and Sarepta’s goal to advance its pre-clinical gene editing program, looking at both viral and non-viral methods to produce a functional gene in order to treat  a broad range of neuromuscular diseases.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: the expected benefits and opportunities related to the collaboration between Sarepta and Genevant may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development. In particular, the collaboration may not result in the discovery of any new therapeutic compounds or any viable treatments suitable for commercialization due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sarepta’s control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates and the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2019, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect Sarepta’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Internet Posting of Information by Sarepta

We routinely post information that may be important to investors in the ‘For Investors’ section of our website at 


www.sarepta.com


. We encourage investors and potential investors to consult our website regularly for important information about us. 

Source: Sarepta Therapeutics, Inc.

Contacts:

Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052, [email protected]
Media: Tracy Sorrentino, 617-301-8566, [email protected]

Genevant Sciences
Pete Zorn, [email protected]

LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), was recently interviewed on the C3 Chat Show Podcast, a series that addresses topics related to entrepreneurship, life experiences and best practices from experts.

The podcast, co-hosted by Sid Vaidya and Eric Gershey, is available for on-demand listening at https://anchor.fm/c3chat.

During the interview, Climaco provided an overview of CNS Pharmaceuticals and recent FDA approval to begin clinical trials on the company’s lead drug candidate, Berubicin, a proposed treatment for glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.

“This is the biggest news we’ve announced since our IPO back in November 2019. The FDA approved an Investigational New Drug application, which allows us to proceed with our clinical trial. Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials for our lead compound, Berubicin, which is a novel treatment for glioblastoma, the most common and aggressive form of primary brain cancer,” Climaco said.

“We have five employees at this company, so we are a tiny little shop,” he continued. “But we have an absolute powerhouse compound. We pushed that through and got the FDA to greenlight a clinical trial, which is really monumental. The Food and Drug Administration of the United States said it’s safe to proceed and investigate this drug in humans.”

“It’s a big day for GBM patients. This is a population that has not seen hardly any innovation for 15 years,” he said. “If you get GBM, the sad reality is you’re probably going to die from it. We think we can change that game.”

“We expect to be enrolling patients as soon as January or February. We know how this drug behaves. It was the subject of a very successful Phase I trial where 44 percent of patients had their disease stabilized or they started to get better. Those are remarkable statistics, because GBM is the deadliest form of brain cancer. Basically no one gets better. But we have a patient who is still alive 14 years after treatment, and that’s just incredible because the median survival for GBM patients following diagnosis is 14-16 months.”

Throughout the podcast, Climaco discussed the difficulties in treating brain cancers because of the brain’s protective covering of specialized cells that shield it from outside infection. He also explained how Berubicin is able to cross the blood-brain barrier and attack tumor cells inside the brain.

Learn more by listening to the full interview at https://anchor.fm/c3chat.

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, visit: www.cnspharma.com

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA) to form Palisade Bio, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to LB1148 for the treatment of postoperative gastrointestinal (GI) dysfunction associated with pediatric heart surgery.  

“Even with high success rates of neonatal heart surgery, longer-term outcomes in pediatric patients are, to a great extent, dependent upon the speed of postoperative recovery of GI function,” said Dr. Michael Dawson, Chief Medical Officer of Leading BioSciences. “By awarding Fast Track Designation to LB1148 for the treatment of pediatric patients undergoing open-heart surgery, the FDA has recognized LB1148’s potential to accelerate return of bowel function and reduce the risk of serious and life-threatening complications associated with corrective surgeries for these patients, a condition for which no therapy currently exists. This is an important acknowledgement and will improve the frequency of our dialogue with the agency as we initiate our pivotal study.”

The FDA Fast Track program is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. With Fast Track designation LBS is eligible for greater access to the FDA for the purpose of expediting clinical development and creates eligibility for accelerated approval and priority review of LB1148.
Previously, LBS announced positive topline data from a Phase 2, randomized, double-blind, placebo-controlled, study that enrolled 120 adult open-heart surgery patients. This trial evaluated return of bowel function in adult patients undergoing open-heart surgery with cardiopulmonary bypass. The LB1148-treated group demonstrated a statistically significant improvement of approximately 30% in the median time to return of normal bowel function as compared to the placebo treatment group (p<0.001). Generally, treatment with LB1148 was well tolerated. Adverse events were similar between the treatment groups and not unexpected for the subject population.

In addition to adult open-heart surgery patients, there is a tremendous unmet need for improving GI recovery in neonates undergoing heart surgery. By accelerating a return of GI function and full feeding following surgery, LB1148 may minimize the risk of developmental delays and other serious complications. LBS is planning to initiate a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial of LB1148 in neonatal patients undergoing elective on-pump open-heart surgery to correct congenital heart defects in 2021.

Tom Hallam, Ph.D., Chief Executive Officer of Leading BioSciences added, “There are currently no therapies available to treat GI dysfunction in pediatric patients undergoing open-heart surgery. We are thrilled that the FDA granted Fast Track designation to LB1148 for this indication. We believe this recognizes LB1148’s potential to demonstrate meaningful improvements in bowel recovery that are commensurate with the improvements demonstrated in our Phase 2 study in adult heart surgery patients.” 

About LB1148

LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays.

About Leading BioSciences, Inc.

Leading BioSciences is developing novel therapeutics designed to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. LBS’ initial focus is combatting the interruption of GI function (ileus) following major surgery in order to reduce recovery times and shorten the duration of patient hospital stays. Additionally, LBS believes that its investigational therapies have the potential to prevent the formation of postoperative adhesions (reducing hospital re-admissions and additional surgeries), as well as to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal mucosal barrier. As of December 2020, Leading BioSciences has entered into a definitive agreement with Seneca Biopharma, Inc. under which a wholly owned subsidiary of Seneca will merge with Leading BioSciences in an all-stock transaction. The combined company is expected to operate under the name Palisade Bio, Inc. (Nasdaq: PALI), upon completion of the merger.

No Offer or Solicitation:


This communication will not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Important Additional Information Will be Filed with the SEC


In connection with the proposed transactions between LBS and Seneca, Seneca filed a registration statement on Form S-4 that contained a proxy statement and prospectus with the Securities Exchange Commission (“SEC”) on December 23, 2020, but the registration statement has not yet become effective. This communication is not a substitute for the registration statement or the proxy statement or any other documents that Seneca may file with the SEC or send to its stockholders in connection with the proposed transactions. BEFORE MAKING ANY VOTING DECISION, SENECA URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SENECA, THE PROPOSED TRANSACTION AND RELATED MATTERS.

You may obtain free copies of the registration statement, proxy statement and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the website maintained by the SEC at www.sec.gov. The registration statement is available free of charge on Seneca’s website at www.senecabio.com, by contacting Seneca’s Investor Relations by phone at (301) 366-4960, or by electronic mail at [email protected]. Investors and stockholders are urged to read the registration statement, proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation


Seneca and LBS, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Seneca’s directors and executive officers is included in Seneca’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 27, 2020, and the proxy statement for Seneca’s 2020 annual meeting of stockholders, filed with the SEC on June 24, 2020. Additional information regarding these persons and their interests in the transaction is included in the proxy statement relating to the transaction. These documents can be obtained free of charge from the sources indicated above.

Cautionary Statement Regarding Forward-Looking Statements


This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to the timing and results of clinical trials, and other statements that are not historical facts.  Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “will,” and similar expressions and their variants.  These forward-looking statements are based upon LBS’s current expectations. Forward-looking statements involve risks and uncertainties, and actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Except as required by law, LBS expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in LBS’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Leading BioSciences Media Relations Contact:

Darren Opland, Ph.D.
LifeSci Communications
[email protected]

Leading BioSciences Investor Relations Contact:

Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

Corporate Contact:

Justin Stege, Ph.D.
[email protected]